Physician profile
Peter D Crosby
NPI 1356337398
$3,490.04
in general payments reported to CMS, 2019-2025
23 companies · $996 in 2025
The $996 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $44.18 · 2021: $265 · 2022: $557 · 2023: $555 · 2024: $1,073 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,598.78 | 2021-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $240.44 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $240.22 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $221.85 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $213.01 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $182.00 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $132.06 | 2021-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $117.85 | 2020-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Sanofi Pasteur INC. | $78.35 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.14 | 2021-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $54.47 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Medtronic, INC. | $50.69 | 2021-2025 | Inpen Smart Insulin Delivery System |
| Biohaven Pharmaceutical Holding Company LTD. | $41.93 | 2022 | |
| Xeris Pharmaceuticals, INC. | $38.96 | 2024-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $32.95 | 2025 | Korlym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $29.29 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $27.10 | 2024 | Contrave |
| Axsome Therapeutics, INC. | $25.80 | 2025 | Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $23.57 | 2025 | |
| Phathom Pharmaceuticals, INC. | $18.17 | 2025 | Voquezna |
| Boston Scientific Corporation | $17.40 | 2025 | Wavewriter Alpha Prime 16 |
| Astellas Pharma US INC | $14.96 | 2024 | Veozah |
| Amgen INC. | $14.05 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Crosby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.